Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab

References

• Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367. doi:10.2147/PPA
   PubMed Web of Science ®Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297. doi:10.3390/ijms18112297
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310. doi:10.1111/jde.2010.37.issue-4
   PubMed Web of Science ®Google Scholar
• Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a Phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89–95. doi:10.1111/jdv.13746
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. doi:10.1016/S0140-6736(15)60125-8
   PubMed Web of Science ®Google Scholar
• Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824–830.e822. doi:10.1016/j.jaad.2018.05.032
   PubMed Web of Science ®Google Scholar
• Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a Phase III study. Br J Dermatol. 2017;177(4):1014–1023. doi:10.1111/bjd.15666
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566. doi:10.1111/j.1365-2133.2007.08315.x
   PubMed Web of Science ®Google Scholar
• Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis. 2018;9(8):147–158. doi:10.1177/2040622318772705
   PubMed Web of Science ®Google Scholar
• Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686–1692. doi:10.1111/jdv.14237
   PubMed Web of Science ®Google Scholar
• Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158(3):549–557. doi:10.1111/j.1365-2133.2007.08236.x
   PubMed Web of Science ®Google Scholar
• Murage MJ, Gilligan A, Tran O, Brinson J, Goldbum O, Burge R Treatment patterns and healthcare utilization and costs for ixekizumab-treated psoriasis patients. AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23–26; 2018; Boston, MA.
   Google Scholar
• Humira® (adalimumab) injection prescribing information; 2018. Available from: https://www.rxabbvie.com/pdf/humira.pdf. Accessed October 1, 2018.
   Google Scholar
• Bonafede M, Johnson BH, Tan DH, Harrison DJ, Stolshek BS. Compliance and cost of biologic therapies for rheumatoid arthritis. Am J Pharm Benefits. 2017;9(5):84–90.
   Google Scholar
• Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–1065.e1054. doi:10.1016/j.jaad.2016.01.048
   PubMed Web of Science ®Google Scholar
• Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm. 2016;22(12):1457–1471. doi:10.18553/jmcp.2016.22.12.1457
   Google Scholar
• Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483–1503. doi:10.2147/PPA
   PubMed Web of Science ®Google Scholar
• Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–2310. doi:10.1185/03007990903126833
   PubMed Web of Science ®Google Scholar
• Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35(30):5642–5655. doi:10.1002/sim.v35.30
   PubMed Web of Science ®Google Scholar
• No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2018;29(5):460–466. doi:10.1080/09546634.2017.1398393
   PubMed Web of Science ®Google Scholar
• van den Reek J, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5. doi:10.1038/jid.2015.171
   PubMed Web of Science ®Google Scholar
• Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14(4):315–326. doi:10.1007/s40257-013-0030-z
   PubMed Web of Science ®Google Scholar
• Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664–674. doi:10.1007/s12325-012-0037-5
   PubMed Web of Science ®Google Scholar
• Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24(5):369–373. doi:10.3109/09546634.2012.755255
   PubMed Web of Science ®Google Scholar
• Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013;24(1):25–33. doi:10.3109/09546634.2012.661038
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201–209. doi:10.18553/jmcp.2015.21.3.201
   PubMedGoogle Scholar
• Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252. doi:10.1111/bjd.2015.172.issue-1
   PubMed Web of Science ®Google Scholar
• Lunder T, Marko P, Koser Kolar N, Kralj B, Kecelj Leskovec N. Drug survival of biologic therapies for the treatment of psoriasis: results of Slovenian national registry. Biologicals. 2018;54:44–49. doi:10.1016/j.biologicals.2018.04.003
   PubMed Web of Science ®Google Scholar
• Malatestinic W, Nordstrom B, Wu JJ, et al. Characteristics and medication use of psoriasis patients who may or may not qualify for randomized controlled trials. J Manag Care Spec Pharm. 2017;23(3):370–381. doi:10.18553/jmcp.2017.16367
   PubMedGoogle Scholar
• Murage MJ, Anderson A, Casso D, et al. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. J Dermatolog Treat. 2019;30:141–149.
   PubMed Web of Science ®Google Scholar
• Seale L, Cardwell LA, Feldman SR. Adherence to biologics in patients with psoriasis. Expert Rev Clin Immunol. 2018;14(2):155–161. doi:10.1080/1744666X.2018.1427065
   PubMed Web of Science ®Google Scholar
• Vilarrasa E, Notario J, Bordas X, Lopez-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74(6):1066–1072. doi:10.1016/j.jaad.2016.01.037
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640. doi:10.1038/jid.2015.208
   PubMed Web of Science ®Google Scholar
• Taltz® (ixekizumab) injection prescribing information. Available from: http://uspl.lilly.com/taltz/taltz.html#pi. Accessed October 1, 2018..
   Google Scholar
• Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018;29:769–774.
   PubMed Web of Science ®Google Scholar
• Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value; August 2018; Available from: https://icer-review.org/wp-content/uploads/2017/11/ICER_Psoriasis_Update_Final_Evidence_Report_080118.pdf. Accessed November 30, 2018..
   Google Scholar